Stevenage Bioscience Catalyst (SBC), an open innovation campus driving collaboration to improve healthcare, located in Hertfordshire, UK, has appointed Ian Tomlinson as Independent Chairman. With extensive pharma and biotech experience as Head of Biopharmaceuticals R&D and Worldwide Business Development at GSK, and Founder and Chief Scientific Officer of Domantis, he will play a key role as the campus continues to expand.
Dr Tomlinson, formerly GSK’s representative on the Board, replaces John Cooper of the Wellcome Trust and the Francis Crick Institute, who has been Interim Chairman since the death of Allan Baxter earlier this year. Cooper will continue on the Board as the Wellcome Trust nominated director, with an announcement on a new GSK representative to be made in due course.
